EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Tabersonine affects osteoclast differentiation, apoptosis and ameliorates bone loss in osteoporotic mice

Hui Shi, Pinghui Zhou, Jingxian Fan, Zhihui Wang, Chengfeng Xu, Nan Zhang, Shiying Bian, Xu Weng, Qin Yang, Mengying Xu, Xishuai Tong, Yingxiao Fu

European Journal of Histochemistry · 20.11.2026 · 70 (4)

DOI: 10.4081/ejh.2026.4546 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Histochemistry, online erschienen am 20.11.2026. Verfasst von Hui Shi und 11 weiteren Autor:innen. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study investigates the effects of tabersonine on osteoclast differentiation, apoptosis, and bone loss in osteoporotic mice. To address these objectives, we performed a series of in vitro and in vivo experiments. In vitro, RAW264.7 cell viability was assessed using the CCK-8 method, and osteoclast-like cells were induced with RANKL. The impact of tabersonine on osteoclast-like cell differentiation was assessed via TRAP staining, while DAPI and TRITC-Phalloidin staining were used to examine nuclear morphology and actin filament organization. Apoptosis in mature osteoclast-like cells was evaluated using Hoechst 33258 staining, and intracellular ROS levels were measured using a commercial assay kit. The expression of genes associated with osteoclast differentiation and apoptosis was analyzed by quantitative real-time PCR, and corresponding protein levels were determined via Western blotting. In vivo, an osteoporosis mouse model was established and treated with tabersonine. The femurs were collected and subjected to micro-CT reconstruction, H&E staining, and TRAP staining to evaluate the extent of bone loss. The results demonstrated that in vitro, tabersonine significantly inhibited osteoclast-like cell differentiation, accompanied by reduced expression of key differentiation-related genes, including MMP-9 and NFATc1, and altered activation of differentiation-associated proteins such as NFATc1, C-Fos, and C-Jun. Furthermore, tabersonine promoted apoptosis in mature osteoclast-like cells, as evidenced by upregulated apoptosis-related genes (Caspase-3 and Bax) and proteins (Caspase-3, Bax, Bcl-2, and Caspase-9). In vivo, tabersonine ameliorated bone loss parameters and reduced osteoclast numbers in femoral tissues of osteoporotic mice. Collectively, these findings suggest that tabersonine suppresses osteoclast-like cell differentiation and facilitates apoptosis of mature osteoclast-like cells, thereby effectively attenuating bone loss in osteoporotic mice.

Zitieren

APA

Shi, H., Zhou, P., Fan, J., Wang, Z., Xu, C., Zhang, N., Bian, S., Weng, X., Yang, Q., Xu, M., Tong, X., & Fu, Y. (2026). Tabersonine affects osteoclast differentiation, apoptosis and ameliorates bone loss in osteoporotic mice. European Journal of Histochemistry, 70(4). https://doi.org/10.4081/ejh.2026.4546

Vancouver

Shi H, Zhou P, Fan J, Wang Z, Xu C, Zhang N, et al. Tabersonine affects osteoclast differentiation, apoptosis and ameliorates bone loss in osteoporotic mice. European Journal of Histochemistry. 2026;70(4). doi:10.4081/ejh.2026.4546

BibTeX
@article{Shi2026,
  author = {Shi, Hui and Zhou, Pinghui and Fan, Jingxian and Wang, Zhihui and Xu, Chengfeng and Zhang, Nan and Bian, Shiying and Weng, Xu and Yang, Qin and Xu, Mengying and Tong, Xishuai and Fu, Yingxiao},
  title = {Tabersonine affects osteoclast differentiation, apoptosis and ameliorates bone loss in osteoporotic mice},
  journal = {European Journal of Histochemistry},
  year = {2026},
  volume = {70},
  number = {4},
  doi = {10.4081/ejh.2026.4546}
}
Kostenlos starten →